William Blair & Company’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-88,295
| Closed | -$268K | – | 1893 |
|
|
2024
Q4 | $268K | Buy |
88,295
+2,297
| +3% | +$10K | ﹤0.01% | 1329 |
|
|
2024
Q3 | $446K | Sell |
85,998
-204,517
| -70% | -$1.02M | ﹤0.01% | 1152 |
|
|
2024
Q2 | $747K | Sell |
290,515
-38,752
| -12% | -$132K | ﹤0.01% | 970 |
|
|
2024
Q1 | $1.62M | Buy |
329,267
+36,318
| +12% | +$215K | 0.01% | 731 |
|
|
2023
Q4 | $2.58M | Sell |
292,949
-33,357
| -10% | -$273K | 0.01% | 620 |
|
|
2023
Q3 | $3.74M | Sell |
326,306
-169,969
| -34% | -$3.27M | 0.01% | 505 |
|
|
2023
Q2 | $12.6M | Buy |
496,275
+189,398
| +62% | +$5.9M | 0.05% | 279 |
|
|
2023
Q1 | $9.88M | Buy |
306,877
+181,372
| +145% | +$5.65M | 0.04% | 307 |
|
|
2022
Q4 | $2.32M | Buy |
125,505
+15,200
| +14% | +$348K | 0.01% | 593 |
|
|
2022
Q3 | $2.98M | Buy |
110,305
+96,112
| +677% | +$1.95M | 0.01% | 531 |
|
|
2022
Q2 | $196K | Buy |
14,193
+1,542
| +12% | +$23.7K | ﹤0.01% | 1431 |
|
|
2022
Q1 | $247K | Sell |
12,651
-300
| -2% | -$4.55K | ﹤0.01% | 1433 |
|
|
2021
Q4 | $211K | Sell |
12,951
-93,280
| -88% | -$1.56M | ﹤0.01% | 1550 |
|
|
2021
Q3 | $2.96M | Buy |
106,231
+35,597
| +50% | +$1.02M | 0.01% | 594 |
|
|
2021
Q2 | $2.09M | Buy |
70,634
+29,120
| +70% | +$840K | 0.01% | 694 |
|
|
2021
Q1 | $1.16M | Buy |
41,514
+21,033
| +103% | +$582K | ﹤0.01% | 848 |
|
|
2020
Q4 | $580K | Buy |
20,481
+9,640
| +89% | +$250K | ﹤0.01% | 1040 |
|
|
2020
Q3 | $273K | Sell |
10,841
-11,895
| -52% | -$312K | ﹤0.01% | 1178 |
|
|
2020
Q2 | $555K | Buy |
22,736
+4,036
| +22% | +$79.7K | ﹤0.01% | 907 |
|
|
2020
Q1 | $277K | Buy |
18,700
+3,250
| +21% | +$67.2K | ﹤0.01% | 1042 |
|
|
2019
Q4 | $251K | Buy |
+15,450
| New | +$240K | ﹤0.01% | 1233 |
|
|
2018
Q2 | – | Sell |
-8,250
| Closed | -$254K | – | 1643 |
|
|
2018
Q1 | $254K | Sell |
8,250
-4,700
| -36% | -$151K | ﹤0.01% | 1134 |
|
|
2017
Q4 | $463K | Buy |
+12,950
| New | +$372K | ﹤0.01% | 990 |
|
|
2015
Q4 | – | Sell |
-22,007
| Closed | -$654K | – | 1283 |
|
|
2015
Q3 | $654K | Buy |
+22,007
| New | +$668K | 0.01% | 887 |
|
Other funds holding RVNC
William Blair & Company's RVNC Position: Q1 2025 in Review
William Blair & Company sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 88,295 shares — an estimated $268K sold.
William Blair & Company first reported a position in RVNC in Q3 2015 and held it in 24 quarters. The position peaked at $12.6M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- William Blair & Company reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- William Blair & Company sold 88,295 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $268K.
- William Blair & Company first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 24 quarters.
- William Blair & Company's Revance Therapeutics, Inc. position peaked at $12.6M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on William Blair & Company's 13F filing for Q1 2025, filed 9 May 2025.